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Background-—Excess adiposity, which affects 69% of US adults, increases coronary heart disease (CHD) risk in an association that
manifests below conventional obesity cut points. The population-level impact on CHD risk that is attainable through modest
adiposity reductions in populations is not well characterized. We estimated the effect of hypothetical reductions in both body mass
index (BMI) and waist circumference (WC) on CHD incidence.
Methods and Results-—The study population included 13 610 ARIC (Atherosclerosis Risk in Communities) participants. Our
hypothetical reduction in BMI or WC was applied relative to the temporal trend, with no hypothetical reduction among those with
BMI >24 or WC >88 cm, respectively. This threshold for hypothetical reduction is near the clinical guidelines for excess adiposity.
CHD risk differences compared the hypothetical reduction with no reduction. Sensitivity analysis was conducted to estimate the
effect of applying the hypothetical BMI reduction at the established overweight cut point of 25. Cumulative 12-year CHD incidence
with no intervention was 6.3% (95% CI, 5.9–6.8%). Risk differences following the hypothetical BMI and WC reductions were 0.6%
(95% CI, 1.0% to 0.1%) and 1.0% (95% CI, 1.4% to 0.5%), respectively. These results were robust for the sensitivity
analyses. Consequently, we estimated that this hypothetical reduction of 5% in BMI and WC, respectively, could have prevented 9%
and 16%, respectively, of the CHD events occurring in this study population over 12 years, after adjustment for established CHD
risk factors.
Conclusions-—Meaningful CHD risk reductions could derive from modest reductions in adiposity attainable through lifestyle
modification. ( J Am Heart Assoc. 2020;9:e012214. DOI: 10.1161/JAHA.119.012214.)
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C oronary heart disease (CHD) is the leading cause ofdeath in the United States.1–3 Although CHD mortality
and incidence declined from 1987 to 2011,4,5 a significant
slowing in the average annual rate of decline was observed,
which may reflect the burden of established risk factors for
CHD such as obesity and diabetes mellitus.6,7 In 2015, an
estimated 69% of the US adult population was overweight and
obese (body mass index [BMI] ≥25; calculated as kg/m2),8
and 9.4% had diabetes mellitus.9
A strong and continuous association has been observed
between total adiposity and CHD,10–12 and studies have
evaluated the effect of reducing adiposity on CHD risk.13,14
Several observational studies have reported an association
between increased adiposity and increased risk of CHD,15,16
whereas others have reported increased risk of CHD mortality
following weight loss17,18; other studies focused mostly on
total adiposity measured by BMI reported no associa-
tion.13,19,20 Lifestyle interventions to reduce obesity-asso-
ciated CHD risk21 focused largely on total adiposity indexed
as BMI, but waist circumference (WC) is a surrogate measure
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for visceral adiposity,22,23 which is associated with CHD even
after adjusting for BMI.24,25 Through its effects on metabolic
dysregulation and vascular structure and function, visceral
adiposity has an important role in assessing modification of
CHD risk.26 The national age-adjusted mean WC increased
from 95.5 cm (95% CI, 94.2–96.8 cm) in 1999–2000 to
98.5 cm (95% CI, 97.5–99.4 cm) in 2011–2012.27 In addi-
tion, the increase in the prevalence of elevated abdominal
adiposity—46.4% (95% CI, 42.1–50.8%) in 1999–2000 to
54.2% (95% CI, 51.3–57%) in 2011–2012—was greater than
expected based on increases in BMI,5 possibly contributing to
the observed slowing in the average annual rate of CHD
decline. WC has a potential but understudied role in the
assessment and modification of CHD risk13,14 because WC is
a reliable and feasible means of estimating central adiposity
at the population level.28,29
Modifiable risk factors for CHD are well established, such
as hypertension30,31 and diabetes mellitus,32–34 which
together mediate much of the obesity-associated metabolic
dysregulation that increases risk of CHD.5,12,35–38 Because
the effect of adiposity on CHD risk likely occurs through the
well-documented adverse effects of excess adiposity on
cardiometabolic intermediaries in the path to CHD, adiposity
represents a modifiable, upstream risk factor for CHD.12
Previous reports have examined the effect on CHD of BMI
interventions,13,14 but little information is available examining
the role of central adiposity, typically approximated by WC. In
addition to evaluating WC, evidence is needed to evaluate the
influence of modest intervention effects. We used the para-
metric g-formula because this approach can estimate the effect
of interventions, such as reductions in modifiable risk factors
such as BMI,39 and overcomes some limitations of standard
regression approaches.40 Avoiding bias in this context requires
consideration of time-dependent confounders that may be
affected by the intervention.41 To estimate the effect of
reductions in adiposity, prior blood levels of, for example,
lipoprotein lipids should be considered as a time-varying
confounder, allowing for effects that reductions in adiposity
may have on subsequent lipoprotein-lipid levels. Because the
customary method of adding changes in both adiposity and
lipoprotein-lipid levels as time-varying covariates in a regres-
sion model can lead to bias,42 we used Robins g-formula43 to
estimate the effect of hypothetical interventions on the risk of
incident CHD. The purpose of this study was to examine the
effect of moderate hypothetical changes (5%) in total (BMI) and
central (WC) adiposity on the incidence of CHD.
Methods
Availability of data and detailed policies for accessing ARIC
(Atherosclerosis Risk in Communities) study data can be
found online.44 The ARIC study data are made available
through the National Heart, Lung, and Blood Institute
BioLINCC repository.45
Study Population
This study was conducted in the community-based, prospec-
tive, and predominantly black and white ARIC study cohort,46
which includes 15 792 adults aged 45 to 64 years. ARIC
cohort participants were recruited using probability sampling
from 4 US communities: Forsyth County, North Carolina;
Jackson, Mississippi; northwest suburbs of Minneapolis,
Minnesota; and Washington County, Maryland. Only black
residents were sampled in the Jackson study area.
Exclusions
Among the 15 792 ARIC participants who attended the first
ARIC visit, we excluded those who reported a race other than
black or white (n=48) and 55 black participants fromMinnesota
andWashington County because of small site-specific numbers.
Also excluded were participants who reported morbidity or
chronic conditions associated with weight gain or loss at
baseline, including 871 with self-reported cancer, 79 taking
heart failure medication, 19 with kidney failure (144 missing
data on kidney function), and 667 with prevalent CHD. We
excluded participants with missing data on baseline covariates
and covariates related to exclusion criteria. For the analysis of
the effect of a hypothetical shift in BMI, we excluded 58
participants missing information on BMI, smoking, hyperten-
sion, or diabetes mellitus and removed outliers by trimming
observations of the baseline BMI distribution (n=241) above the
race- and gender-specific 99th percentile of BMI (50.3, 43.5,
Clinical Perspective
What Is New?
• Estimation of the effect of a hypothetical reduction in body
mass index and waist circumference on coronary heart
disease risk in a cohort of black and white people.
• Stronger impact on the risk of coronary heart disease was
observed for modification of waist circumference than body
mass index.
What Are the Clinical Implications?
• These observational results suggest that modest reductions
in adiposity measures in midlife have beneficial effects on
the risk of coronary heart disease.
• Recommendations for achievable targets of waist circum-
ference modification consistent with lifestyle modification
may improve coronary heart disease risk.
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42.0, and 39.6 for black women, white women, black men, and
white men, respectively) or lower than the 1st percentile (18.8,
18.1, 18.0, and 19.9, respectively) to arrive at our analytic set of
13 610 participants. For our analytic set of 13 301 participants
for the WC analysis, we excluded 305 individuals missing
information on WC, smoking, or BMI and trimmed observations
below the race- and gender-specific 1st percentile and above the
99th percentile of the baseline distribution of WC. The 99th
percentile of WC was 140, 130, 127, and 124 cm for black
women, white women, black men, and white men, respectively,
and the 1st percentile of WC was 70, 68, 99, and 99 cm,
respectively.
Exposure, Covariate, and Outcome
Ascertainment
Demographic and health characteristics were collected at the
first examination during 1987–1989. Follow-up interviews
were carried out approximately every 3 years for a total of 7
examination visits. Institutional review boards at each site
approved the ARIC study, and all participants completed
informed consent at each examination visit.46,47 We limited
our analysis to the first 4 triennial exams (1987–1999).
At each ARIC visit, standardized physical examinations and
interviewer-administered questionnaires were used to gather
behavioral information, medical data, and contextual data. All
measurements taken at the ARIC examinations were collected
by trained technicians following a common study protocol
standardized across the repeated examination visits.46 Annual
follow-up telephone interviews ascertained health outcomes
and hospitalizations.
Covariate information was ascertained during each of the 4
triennial study visits for BMI, WC (cm), cigarette smoking
status (current compared with never and previous), hyperten-
sion (blood pressure >140/90 mm Hg or use of antihyper-
tension medication within 2 weeks), and diabetes mellitus
(fasting glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/
dL, diabetes mellitus medication use, or self-reported physi-
cian diagnosis).
Ascertainment of CHD events was conducted through
annual telephone interviews of health events and hospitaliza-
tions and active surveillance of discharge lists from local
hospitals and death certificates from state vital statistics
offices. CHD events were validated by a morbidity and
mortality classification committee. We defined incident CHD
as the first occurrence of definite or probable hospitalized
myocardial infarction, a definite CHD death, or an unrecog-
nized myocardial infarction detected on 12-lead ECG.
Study participant follow-up extended until the first CHD
event, CHD death, non-CHD death, or absence from an ARIC
examination visit. If participants missed a study visit, they
were considered to be at risk for incidence of CHD, CHD
death, and non-CHD death for 3 years after that missed visit.
For the purposes of this study, we administratively censored
participants at 3 years after the fourth examination visit for
consistent follow-up time throughout the ARIC study, as there
are 3 years between each study visit. When our study was
conducted, 3 years after visit 5 had not occurred.
Statistical Analysis
We estimated the risk of CHD under the specified interventions
with the parametric g-formula,14,39,40,43,48 a generalization of
standardization for time-varying exposures and confounders.41
Regression models were fit on the entire study population to
predict each time-varying covariate, non-CHD death, and CHD.
The fitted regression models were used to simulate CHD for
each time period in each intervention, in the following sequence:
use the observed covariate values at baseline, predict the joint
distribution of the time-varying covariates at the next time point,
set the values of the covariates to the values determined by the
hypothetical intervention, predict the probability of CHD and
non-CHD death using these new values, repeat all but the first
step for each time period and estimate the population risk as the
average of the subject-specific risks. Key assumptions of the
parametric g-formula are that there is no residual confounding
and no model misspecification.14,39,40,43 The validity of the
parametric models was assessed by comparing the observed
means of the time-varying covariates risk of death and CHDwith
those predicted by the models. We used nonparametric
bootstrapping with 200 samples to estimate the 95% CIs. We
estimated the standard error to calculate the 95% CI as
cumulative incidence 1.969SD (cumulative incidence) and
risk difference1.969SD (risk difference). Key assumptions of
the parametric g-formula are that there is no residual confound-
ing and no model misspecification. Another assumption is
treatment version irrelevance, implying that the effect of a shift
in BMI applied as a hypothetical change is the same as it would
have been if it had occurred naturally.
Baseline covariates included in each of the regression
models were race, sex, and education. CHD was included as
annual incidence, and we used a carry-forward method to fill
in the covariates between the approximately triennial ARIC
study visits for WC, BMI, diabetes mellitus, hypertension, and
smoking status. Time-varying covariates included in each of
the regression models were years at risk for CHD, diabetes
mellitus, hypertension, smoking, and measure of adiposity
specific to each analysis of a hypothetical 5% reduction in
total (BMI) or central (WC) adiposity.
For the BMI and WC analysis, we resampled with replace-
ment for 1 360 000 and 1 330 000 “pseudo-participants,”
respectively. No hypothetical adiposity reductionwas applied to
this simulated data set, which is identified as the “natural
course.” We applied a 5% reduction in BMI relative to the
DOI: 10.1161/JAHA.119.012214 Journal of the American Heart Association 3















trajectory of BMI from the natural course within the population
who were aged <65 years and had BMI >24 (for the BMI
analysis) or WC >88 (for the WC analysis). The cumulative
incidence of CHD was estimated while allowing for competing
risks from death or censoring.49 All analyses were conducted
using SAS 9.4 (SAS Institute). As a sensitivity analysis, we
estimated the effect of applying the hypothetical BMI reduction
at the established BMI cut point for overweight of BMI 25.
Results
Characteristics of Study Participants
Over 12 years of follow-up, 763 and 712 incident CHD
events occurred among the 13 610 (BMI analysis) and
13 301 (WC analysis) middle-aged participants, respectively,
in this cohort. Participants with incident CHD were more likely
to be male, to be white, and to have less than a high school
education compared with those without incident CHD.
Smoking, diabetes mellitus, and hypertension were more
frequent at baseline among those who developed incident
CHD compared with those without incident CHD. Participants
who did not develop incident CHD had more favorable
cardiometabolic risk profiles compared with those who
developed incident CHD (Table 1).
The median BMI was between 26.9 and 28.2 in the natural
course and between 24.7 and 25.6 in the population in which a
hypothetical 5% shift in BMI was applied to those with a BMI
>24 who were aged<65 years. The median WC was between
95.9 and 100.6 cm in the natural course and between 88.6 and
93.8 cm in the population exposed to a hypothetical 5% shift in
WC. For the BMI analysis, the cumulative incidence of CHD
under the natural course was 6.3% (95% CI, 5.9–6.8%) and 5.8%
(95% CI, 5.2–6.4%) following the hypothetical BMI change. The
risk difference was0.6% (95% CI,1.0% to0.1%) comparing
no BMI change with the hypothetical BMI change (Table 2). For
the WC analysis, the cumulative incidence of CHD, which
started to diverge at around 5 years of follow-up in the natural
course, was 6.2% (95% CI, 5.8–6.7%) and 5.2% (95% CI, 4.6–
5.9%) following the hypothetical WC change. The risk difference
was 1.0% (95% CI, 1.4% to 0.5%) comparing the
hypothetical WC change with no WC change (Table 2).
Consequently, we estimated that this hypothetical reduction
of 5% in BMI and WC, respectively, after adjustment for race,
sex, education, diabetes mellitus, hypertension, and smoking,
could have prevented 9% and 16% of the CHD events occurring
in this study population over 12 years.
Discussion
Our results indicate that plausible and meaningful reductions
in CHD risk could be achieved by modest reductions in total
(BMI) and central (WC) adiposity over the course of 12 years,
relative to the observed temporal trends. Reduction in CHD
risk was larger with a hypothetical WC reduction compared
with BMI reduction. Our hypothetical reductions in adiposity
were consistent with the clinically recommended weight
reductions of 5% to 10% for people who are overweight.50 We
applied a hypothetical shift to the population distribution of
adiposity at a threshold that was established to be near the
clinical guidelines for excess adiposity; for the ARIC popula-
tion, this was at the 24th percentile of the baseline
distribution of BMI and WC. Unlike BMI, WC does not have
well-established clinical guidelines for excess adiposity;
therefore, we used an equivalent threshold for WC by applying
a hypothetical shift at the 24th percentile of the WC
distribution, which corresponded to 88 cm.
The larger risk reduction in CHD following a hypothetical
WC reduction compared with a hypothetical BMI reduction
suggests a stronger metabolic impact of WC modifications
and the associated risk of CHD.22–24 We considered that this
larger risk reduction following a hypothetical WC reduction
compared with a BMI reduction could be related to residual
confounding if preclinical disease is present51; however, we
adjusted for morbidity and chronic conditions at baseline that
were related to weight change.13
Other studies have demonstrated associations between
abdominal adiposity and CHD independent of BMI.52–55
Furthermore, genetic evidence supports a causal association
between abdominal adiposity and development of CHD.56 WC
was a better predictor of risk for developing diabetes mellitus
than other anthropometric measures in the DPP (Diabetes
Prevention Program).57 Comparing our findings with those of
large clinical trials such as the DPP, the 5% reduction we
applied to WC (4.4–5.5 cm) is similar to the 4-cm WC
reduction observed in the DPP, which was associated with a
24% reduction in risk of diabetes mellitus over 10 years of
follow-up among participants who were randomized to an
intensive lifestyle intervention.58
The effect of modest hypothetical shifts in the population
distribution of BMI on incidence of CHD was examined13,14
using data from the Nurse’s Health Study. The authors
modeled several hypothetical lifestyle interventions,14 one of
which was targeted maintenance of BMI <25; the authors did
not observe this intervention having an effect on the
incidence of CHD. Because this BMI reduction over the 2-
year time period was unrealistic, the authors proposed (but
did not test) a hypothetical intervention that would reduce
BMI by a small percentage (ie, 5%), which is similar to the
hypothetical intervention that we implemented.
A focus on central adiposity also opens opportunities for
public health messages that address modification in WC or
perhaps clothing size as a more tangible measure than ratio
formulation such as BMI. Moderate-intensity exercise is
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associated with significant reductions in total fat, visceral fat,
and skeletal muscle lipid content.59 Increased cardiometabolic
fitness is associated with reduction in mortality and morbidity
independent of BMI.60 Such an approach that targets central
adiposity may also encourage those who appear resistant to
substantial weight loss despite considerable effort.
Population-based programs aim to achieve sustained
effects of modest magnitude, but wide penetration is needed
to complement clinical efforts that target excess adiposity
and to influence cultural norms and trends that shift adiposity
levels in populations.11,61–64 Waist girth and central adiposity
tap into cultural norms and popular perceptions different from
Table 1. Characteristics of the Study Population at Baseline by Incidence of CHD
Characteristic
Incident CHD Without Incident CHD
BMI Analysis, n=763 WC Analysis, n=712 BMI Analysis, n=12 847 WC Analysis, n=12 589
Female 254 (33) 230 (32) 7356 (57) 7208 (57)
Black 207 (27) 190 (27) 3490 (47) 3419 (27)
Less than HS graduate 230 (30) 211 (30) 2892 (23) 2828 (23)
HS graduate or vocational school 291 (38) 270 (38) 5258 (41) 5162 (41)
Some college or college graduate 241 (32) 230 (32) 4681 (36) 4583 (36)
Current smoking 221 (29) 285 (40) 2032 (16) 3423 (27)
Diabetes mellitus 213 (28) 242 (34) 1867 (15) 2402 (19)
Hypertension 450 (59) 487 (68) 5995 (47) 7106 (57)
Follow-up, y 6.0 (3.0–8.8) 5.8 (3.0–8.6) 11.8 (9.0–11.9) 11.8 (9.1–11.9)
Age, y 62 (57–66) 62 (56–66) 54 (49–59) 63 (59–68)
BMI, kg/m2 27.8 (25.1–31.0) NA 26.8 (24.0–30.3) NA
WC, cm NA 102 (94–99) NA 100 (92–99)
SBP, mm Hg 126 (115–140)* 126 (115–140) 118 (108–130)† 118 (108–130)
FPG, mg/dL 104.0 (95–122.3) 104.0 (95–122.3) 99.0 (92.4–106.9) 99 (92.4–107)
TC, mg/dL 221 (195–248)‡ 222 (196–249) 212 (186–239)§ 212 (186–239)
HDL-C 41.4 (34.7–51.0)k 41 (34–51) 50.0 (40.4–61.6)¶ 49.1 (40.4–61.6)
Data are from the ARIC (Atherosclerosis Risk in Communities) study (1987–1999) and are shown as n (%) or median (interquartile range). BMI analysis: n=13 610; WC analysis: n=13 301.
Diabetes mellitus was defined as fasting glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, diabetes medication use, or self-reported physician diagnosis. Hypertension was defined
as blood pressure >140/90 mm Hg or use of antihypertension medication within 2 weeks. BMI indicates body mass index; CHD, coronary heart disease; FPG, fasting plasma glucose;







Table 2. Estimated Cumulative 12-Year Incidence and Risk Difference of CHD for the Natural Course Cohort Compared With the
Cohort With a Hypothetical 5% Shift in the Population Distribution of Adiposity
Cohort* Measure of Effect Estimate (%)† 95% CI
Natural course for BMI Incidence 6.3 5.9–6.8
Hypothetical 5% BMI reduction Incidence 5.8 5.2–6.4
Natural course vs hypothetical reduction Risk difference 0.6 1.0 to 0.1
Natural course for WC Incidence 6.2 5.8–6.7
Hypothetical 5% reduction in WC if WC >88 cm Incidence 5.2 4.6–5.9
Natural course vs hypothetical WC reduction Risk difference 1.0 1.4 to 0.5
Data are from the ARIC (Atherosclerosis Risk in Communities) study (1987–1999). BMI indicates body mass index; CHD, coronary heart disease; WC, waist circumference.
*For the BMI and WC analyses, there were 763 and 712 CHD events among 13 610 and 13 301 ARIC participants, respectively, after 12 years of follow-up.
†Baseline covariates included in the models were age, sex, race, and education. Time-varying covariates included in the models were years at risk for CHD, diabetes mellitus, hypertension,
smoking, and measure of adiposity specific to each analysis of a hypothetical 5% reduction in total (BMI) or central (WC) adiposity.
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those surrounding BMI and total adiposity,65,66 as reflected in
messages in the media and health-product outlets. Our results
warrant replication in other population-based longitudinal
studies with access to cultural, racial/ethnic, and socioeco-
nomic diversity. These results also suggest the need for
assessments of the relative merit of hypothetical shifts in WC
and BMI distributions for other health outcomes influenced by
adiposity and more closely linked causally and temporally to
adiposity than is the case for CHD.
Our analyses were limited to the initial 4 visits of the ARIC
cohort; as a result, the length of our follow-up likely did not
fully capture the long-term impact of adiposity at midlife on
the risk of CHD during the life epochs when the incidence of
CHD is highest. Because the use of WC as a measure of
adiposity is reportedly not accurate in people with a BMI
>40,50 we excluded participants at the upper and lower 1% of
the baseline population distribution of WC; this was also done
for the BMI analysis. Consequently, our estimates are not
generalizable to the excluded segment of the population. The
strengths of our study derive from estimation of the effect of a
hypothetical reduction in BMI and WC on the incidence of
CHD in a cohort of black and white men and women, to our
knowledge, for the first time. This report adds new informa-
tion to the literature on the effects of hypothetical shifts in
total and central adiposity on the incidence of CHD in a
middle-aged black and white cohort. Declines in mortality and
incidence of CHD have been reported over the past decade,
and ongoing primary prevention of risk factors for CHD would
be required to continue the trajectory of these declines.67
The population distribution of adiposity is dynamic and
subject to diverse influences11,68,69 and temporal trends.6,7
Desirable shifts in population distributions of adiposity are the
focus of public health policies aimed at serving sizes, limits on
sugar-sweetened beverages,70–72 subsidies for healthier food
choices, and increased accessibility for physical activity, among
others. Using CHD as a sentinel condition, our results estimate a
modest effect on the incidence of CHD following moderate,
population-wide shifts in central adiposity and, to a lesserdegree,
total adiposity. Although traditionally focused on total adiposity,
clinical and public health recommendations that promote health
and longevity should consider achievable targets for WC
modification, perhaps through lifestyle modification.
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